AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 38-43 , February 2010

Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures

References 

  1. Roberts AW, Visconti JA. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm. 1972;29:828–834
  2. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 1983;5:1033–1048
  3. Monroe S, Polk R. Antimicrobial use and bacterial resistance. Curr Opin Microbiol. 2000;3:496–501
  4. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resistance Updates. 2000;3:303–311
  5. Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–S345
  6. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era?. Arch Med Res. 2005;36:697–705
  7. French GL. Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev. 2005;57:1514–1527
  8. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–177
  9. Kunin CM, Lipton HL, Tupasi T, Sacks T, Scheckler WE, Jivani A, et al. Social, behavioral, and practical factors affecting antibiotic use worldwide: report of Task Force 4. Rev Infect Dis. 1987;9(Suppl 3):S270–S285
  10. Istúriz RE, Carbon C. Antibiotic use in developing countries. Infect Control Hosp Epidemiol. 2000;21:394–397
  11. Radyowijati A, Haak H. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc Sci Med. 2003;57:733–744
  12. Thamlikitkul V, Danchaivijitr S, Kongpattanakul S, Ckokloikaew S. Impact of an educational program on antibiotic use in a tertiary care hospital in a developing country. J Clin Epidemiol. 1998;51:773–778
  13. Sáez-Llorens X, Castrejón de Wong MM, Castaño E, De Suman O, De Moros D, De Atencio I. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J. 2000;19:200–206
  14. Ozkurt Z, Erol S, Kadanali A, Ertek M, Ozden K, Tasyaran MA. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists. Jpn J Infect Dis. 2005;58:338–343
  15. Raveh D, Muallem-Zilcha E, Greenberg A, Wiener-Well Y, Schlesinger Y, Yinnon AM. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. QJM. 2006;99:397–406
  16. Siddiqui S, Hussein K, Manasia R, Samad A, Salahuddin A, Zafar A, et al. Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country. J Pak Med Assoc. 2007;57:484–487
  17. Falagas ME, Bliziotis IA, Michalopoulos A, Sermaides G, Papaioannou VE, Nikita D, et al. Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance. J Chemother. 2007;19:178–184
  18. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med. 1993;94:281–288
  19. Burke JP. Antibiotic resistance—squeezing the balloon?. JAMA. 1998;280:1270–1271

 Conflicts of interest: None to report.

PII: S0196-6553(09)00625-7

doi: 10.1016/j.ajic.2009.04.288

AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 38-43 , February 2010

Article Tools